Role of isavuconazole in the treatment of invasive fungal infections.

dc.contributor.author

Wilson, Dustin T

dc.contributor.author

Dimondi, V Paul

dc.contributor.author

Johnson, Steven W

dc.contributor.author

Jones, Travis M

dc.contributor.author

Drew, Richard H

dc.coverage.spatial

New Zealand

dc.date.accessioned

2016-12-01T16:56:49Z

dc.date.issued

2016

dc.description.abstract

Despite recent advances in both diagnosis and prevention, the incidence of invasive fungal infections continues to rise. Available antifungal agents to treat invasive fungal infections include polyenes, triazoles, and echinocandins. Unfortunately, individual agents within each class may be limited by spectrum of activity, resistance, lack of oral formulations, significant adverse event profiles, substantial drug-drug interactions, and/or variable pharmacokinetic profiles. Isavuconazole, a second-generation triazole, was approved by the US Food and Drug Administration in March 2015 and the European Medicines Agency in July 2015 for the treatment of adults with invasive aspergillosis (IA) or mucormycosis. Similar to amphotericin B and posaconazole, isavuconazole exhibits a broad spectrum of in vitro activity against yeasts, dimorphic fungi, and molds. Isavuconazole is available in both oral and intravenous formulations, exhibits a favorable safety profile (notably the absence of QTc prolongation), and reduced drug-drug interactions (relative to voriconazole). Phase 3 studies have evaluated the efficacy of isavuconazole in the management of IA, mucormycosis, and invasive candidiasis. Based on the results of these studies, isavuconazole appears to be a viable treatment option for patients with IA as well as those patients with mucormycosis who are not able to tolerate or fail amphotericin B or posaconazole therapy. In contrast, evidence of isavuconazole for invasive candidiasis (relative to comparator agents such as echinocandins) is not as robust. Therefore, isavuconazole use for invasive candidiasis may initially be reserved as a step-down oral option in those patients who cannot receive other azoles due to tolerability or spectrum of activity limitations. Post-marketing surveillance of isavuconazole will be important to better understand the safety and efficacy of this agent, as well as to better define the need for isavuconazole serum concentration monitoring.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/27536124

dc.identifier

tcrm-12-1197

dc.identifier.issn

1176-6336

dc.identifier.uri

https://hdl.handle.net/10161/13075

dc.language

eng

dc.publisher

Informa UK Limited

dc.relation.ispartof

Ther Clin Risk Manag

dc.relation.isversionof

10.2147/TCRM.S90335

dc.subject

Mucormycetes

dc.subject

antifungal

dc.subject

aspergillosis

dc.subject

azole

dc.subject

isavuconazole

dc.subject

mucormycosis

dc.title

Role of isavuconazole in the treatment of invasive fungal infections.

dc.type

Journal article

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/27536124

pubs.begin-page

1197

pubs.end-page

1206

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

School of Medicine

pubs.publication-status

Published online

pubs.volume

12

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Role of isavuconazole in the treatment of invasive fungal infections.pdf
Size:
329.4 KB
Format:
Adobe Portable Document Format